Stock Track | Veracyte Soars 7.73% on Strong Q1 Earnings Beat and Raised 2026 Guidance

Stock Track05-06

Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.

The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by a substantial margin. Revenue for the quarter reached $139.1 million, surpassing estimates and representing a 21% year-over-year increase. Key drivers included a 30% growth in Decipher test revenue and a 21% growth in Afirma test revenue, contributing to a net income rise of 307% to $28.7 million.

Investor sentiment was further bolstered as Veracyte raised its 2026 guidance, increasing its total revenue outlook to a range of $582 million to $592 million and projecting an adjusted EBITDA margin greater than 26%. The positive developments were complemented by analyst action, with Leerink Partners raising its price target on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144893183?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144893183","market":"nz","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 7.73% on Strong Q1 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.</p><p>The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by a substantial margin. Revenue for the quarter reached $139.1 million, surpassing estimates and representing a 21% year-over-year increase. Key drivers included a 30% growth in Decipher test revenue and a 21% growth in Afirma test revenue, contributing to a net income rise of 307% to $28.7 million.</p><p>Investor sentiment was further bolstered as Veracyte raised its 2026 guidance, increasing its total revenue outlook to a range of $582 million to $592 million and projecting an adjusted EBITDA margin greater than 26%. The positive developments were complemented by analyst action, with Leerink Partners raising its price target on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 7.73% on Strong Q1 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 7.73% on Strong Q1 Earnings Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 14:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.</p><p>The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by a substantial margin. Revenue for the quarter reached $139.1 million, surpassing estimates and representing a 21% year-over-year increase. Key drivers included a 30% growth in Decipher test revenue and a 21% growth in Afirma test revenue, contributing to a net income rise of 307% to $28.7 million.</p><p>Investor sentiment was further bolstered as Veracyte raised its 2026 guidance, increasing its total revenue outlook to a range of $582 million to $592 million and projecting an adjusted EBITDA margin greater than 26%. The positive developments were complemented by analyst action, with Leerink Partners raising its price target on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1144893183","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144893183","pubTimestamp":1778048277,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票追踪|Veracyte因第一季度盈利强劲增长并上调2026年指引而飙升7.73%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by a substantial margin. Revenue for the quarter reached $139.1 million, surpassing estimates and representing a 21% year-over-year increase. Key drivers included a 30% growth in Decipher test revenue and a 21% growth in Afirma test revenue, contributing to a net income rise of 307% to $28.7 million.Investor sentiment was further bolstered as Veracyte raised its 2026 guidance, increasing its total revenue outlook to a range of $582 million to $592 million and projecting an adjusted EBITDA margin greater than 26%. The positive developments were complemented by analyst action, with Leerink Partners raising its price target on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144893183","isCrawlerRequest":true}